ILCA 2023 | Liquid Biopsy Technology Based on Methylated SEPT9 Has the Potential to Establish a New Early Diagnosis System for Liver Cancer

ILCA 2023 | Liquid Biopsy Technology Based on Methylated SEPT9 Has the Potential to Establish a New Early Diagnosis System for Liver Cancer

2024.01.31
 Liver cancer is one of the malignant tumors with a high incidence and mortality rate in China. Most patients are clinically diagnosed late, with a high rate of postoperative recurrence and metastasis, which has become a significant factor affecting patient prognosis. There is an urgent need for technology that can effectively detect early liver cancer, monitor treatment effects in real-time, and prevent metastasis. Liquid biopsy technology has attracted attention in recent years as a new detection method. It is non-invasive, sensitive, and dynamic, showing promise in early tumor diagnosis, personalized medication guidance, and treatment monitoring. At the 17th International Liver Cancer Association Annual Meeting (ILCA 2023), Dr. Issei Saeki from School of Medicine of Yamaguchi University,Japan, reported a study (Abstract number: O-11) that assessed the clinical application value of liquid biopsy technology based on the methylated SEPT9 test for early diagnosis of non-viral hepatitis-related hepatocellular carcinoma (N-HCC).
ILCA 2023 | When HIV Infection Coexists with HCC: Patient Clinical Features, Treatment Status, and Outcomes

ILCA 2023 | When HIV Infection Coexists with HCC: Patient Clinical Features, Treatment Status, and Outcomes

2024.01.31
 After the HIV virus enters the human body, it first destroys the immune system, leading to a rapid decline in immunity. Consequently, the body becomes more susceptible to various infections and complications, the most common of which are infections in different systems and malignant tumors. As the life expectancy of people living with HIV (PLWH) increases, cases of coexisting malignant tumors are also on the rise. From September 7-9, 2023, the seventeenth International Liver Cancer Association (ILCA) annual meeting (ILCA 2023) was grandly held in Amsterdam, the capital of the Netherlands. At this conference, Dr. Eleonora Alimenti from the University of Pavia, Italy, orally presented the clinical features, treatment status, and clinical outcomes of PLWH coexisting with HCC at Lombardy's Third Hospital in Italy (Conference Abstract: O-07), drawing significant attention.
Dr. Qiang Gao: The Complexity and Diversity of Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma

Dr. Qiang Gao: The Complexity and Diversity of Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma

2024.01.31
 Intrahepatic cholangiocarcinoma (ICC) refers to adenocarcinoma originating from the epithelium of secondary bile ducts and their branches, accounting for 10%-15% of primary malignant tumors in the liver. In recent years, the incidence of ICC has been rising significantly, garnering increasing clinical attention. While ICC and hepatocellular carcinoma (HCC) both belong to primary liver cancers, they have distinct biological characteristics. The complex disease characteristics and prognosis pose significant challenges for ICC's clinical treatment. From September 7-9, 2023, the 17th annual meeting of the International Liver Cancer Association (ILCA) was grandly held in Amsterdam, Netherlands. At the conference, Dr. Qiang Gao from Zhongshan Hospital, Fudan University, China, shared recent advancements in the study of tumor-immune interactions in ICC. This article compiles an in-depth interview with Dr. Gao for our readers.